A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: MK-0941; Drug: Metformin; Drug: Glimepiride

Study type: Interventional

Funder types: Industry

Identifiers

NCT00792935

0941-017

2008_589

CTRI/2009/091/000154 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking metformin for type 2 diabetes.

Enrollment: 143 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient has type 2 diabetes mellitus
• Between the ages of 18 and 70

Exclusion criteria

• Patient has a history of type 1 diabetes mellitus or ketoacidosis.
• Patient is on a weight loss program and is not in the maintenance phase or is taking weight loss medication.
• Patient has had surgery within 30 days of starting the study or has planned major surgery during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

143 participants in 2 patient groups

MK-0941

Experimental group

Treatment:

Drug: MK-0941

Drug: Metformin

Glimepiride

Active Comparator group

Treatment:

Drug: Glimepiride

Drug: Metformin